07-05-2012

Evotec AG announced that Evotec has entered into a multi-year compound management agreement with the United States EPA. The contract covers a period of five years and has a total value of up to EUR7.7 million (approx. USD 10 million).Under the agreement Evotec, through its San Francisco ...

more

15-01-2007

PerkinElmer, Inc. reported that it has successfully completed two previously announced acquisitions that will extend its portfolio of advanced tools for cellular analysis and High Content Screening (HCS). In the fourth quarter of 2006, the Company announced its intent to acquire Euroscreen ...

more

04-12-2006

PerkinElmer, Inc. announced that it has signed a definitive agreement with Evotec AG to acquire its majority owned subsidiary, Evotec Technologies GmbH, in a cash transaction valued at approximately EUR 23 million. The transaction is subject to regulatory approvals and other customary closing ...

more

25-07-2005

Evotec AG and Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company announced that they have entered into agreements whereby Evotec will provide pharmaceutical discovery and chemical development services to P&GP. Under the terms of the agreements, P&GP ...

more

19-07-2004

Evotec OAI AG a leading partner for integrated, high-value-added drug discovery and development solutions, today announced that Biogen Idec has selected Evotec OAI as one of its service providers for chemical process research and development and cGMP manufacturing. The companies have ...

more

12-05-2004

Evotec OAI and Roche have a long-standing relationship that includes three chemistry alliances since 2001 when Evotec OAI began supporting four Roche sites in the design and synthesis of high quality chemical compounds. These compounds were added to the Roche compound library collection and ...

more

16-01-2004

Evotec OAI AG and Rib-X Pharmaceuticals, Inc., announced the formation of a medicinal chemistry partnership. Scientists from Rib-X and Evotec OAI will collaborate on several research programmes. Evotec OAI will be utilising its state-of-the-art integrated medicinal chemistry and parallel ...

more

25-06-2003

Evotec OAI, a partner for integrated high-value-added drug discovery services to the pharmaceutical and biotechnology industries, and Axxima Pharmaceuticals AG, a drug discovery and development company leading the field of pathogen-host signal transduction, today announced that they have ...

more

25-11-2002

Evotec OAI AG announced a one-year extension of its Focused Library Agreement with Solvay Pharmaceuticals which was originally signed in January 2001. Applying Evotec OAI's world class expertise in high-speed and computational chemistry, a dedicated team of Evotec OAI chemists will design ...

more

08-11-2002

Evotec OAI AG, a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, announced today that it has signed a medicinal chemistry optimisation programme agreement with British Biotech plc , a research and development stage biopharmaceutical ...

more